title: [Therapeutic results: tacrine].
abstract: Tacrine is the first drug having been demonstrated as effective for the treatment of mild and moderate forms of Alzheimer's disease. It works as a potent centrally active inhibitor of acetylcholinesterase and therefore has cholinomimetic properties. The authors evaluate the costs/benefits ratio of this drug taking into account clinical and economical data.
authors.affiliation: Service de Neurologie, Hôpital Erasme, Bruxelles.
authors.forename: M
authors.initials: M
authors.lastname: Ventura
authors.forename: J
authors.initials: J
authors.lastname: Sternon
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D018697:Nootropic Agents / Q000191:economics / Q000627:therapeutic use*; D013619:Tacrine / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D013619:Tacrine
vernacular_title: Actualité thérapeutique: la tacrine.